The collaboration between BioMed X and Novo Nordisk marks a significant step forward in the quest to overcome one of the most pressing challenges in drug development: the oral delivery of therapeutic peptides. The joint project, titled ‘Prolonged Retention of Oral Peptide Formulations in the Gut,’ seeks to develop novel technologies that enhance the absorption and bioavailability of peptide-based drugs by ensuring their prolonged retention in the lower small intestine.
Current oral peptide formulations face limitations due to low intestinal permeability and rapid transit through the gastrointestinal tract. This collaboration aims to address these issues by creating formulations that allow for continuous release and efficient absorption of peptides, thereby improving patient compliance without compromising safety or causing gastrointestinal obstruction. The research will be conducted at BioMed X’s facility in Heidelberg, Germany, where a new team will be assembled to focus on this innovative project.
Dr. Christian Tidona, CEO of BioMed X, expressed enthusiasm about the partnership, highlighting the potential impact on patients’ lives by making peptide drugs, such as GLP-1 receptor agonists, orally available. Stephen Buckley, Scientific Vice President at Novo Nordisk, emphasized the company’s commitment to pushing the boundaries of science through both internal and external innovation, underscoring the significance of this collaboration in advancing oral peptide formulation technologies.
Researchers interested in contributing to this groundbreaking project are encouraged to submit their proposals via the BioMed X Career Space before October 12, 2025. This initiative not only represents a pivotal moment in drug delivery research but also exemplifies the power of collaboration between academia and industry in addressing complex biomedical challenges.
This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery.